OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
September 02, 2023
The ROSS line of Double Planetary Mixers are fully customized and engineered for efficient processing of medical-grade silicone formulations in a portable workstation.
September 01, 2023
Interpreting data and understanding the various components of biologic drug substance testing is an important skillset to know as a lab personnel.
August 31, 2023
Bristol Myers Squibb has joined Cellares’ Technology Adoption Partnership program just as Cellares launches operations as an integrated development and manufacturing organization.
The Centers for Medicare & Medicaid Services (CMS) has announced the first 10 drugs covered under Medicare Part D selected for negotiation.
Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) is approved as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes.
The updated vaccine will be ready to ship following a positive European Commission review.
Extensive research on various gene editing techniques could inform the future of mRNA therapies.
Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.
Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.
August 30, 2023
The new products aim to aid consumers with menopause and eye health-related issues.